prikaz prve stranice dokumenta Nirmatrelvir/ritonavir in COVID-19 patients with haematological malignancies: a report from the EPICOVIDEHA registry
  Preuzmi
PDF 1.15 MB
Znanstveni rad - Izvorni znanstveni rad
Nirmatrelvir/ritonavir in COVID-19 patients with haematological malignancies: a report from the EPICOVIDEHA registry
eClinicalMedicine, 58 (2023); 101939. https://doi.org/10.1016/j.eclinm.2023.101939
(EPICOVIDEHA registry) Salmanton-García, Jon; Marchesi, Francesco; Gomes da Silva, Maria; Farina, Francesca; Dávila-Valls, Julio; Bilgin, Yavuz M.; Glenthøj, Andreas; Falces-Romero, Iker; Van Doesum, Jaap; Labrador, Jorge; Buquicchio, Caterina; El-Ashwah, Shaimaa; Petzer, Verena; Van Praet, Jens; Schönlein, Martin; Dargenio, Michelina; Méndez, Gustavo-Adolfo; Meers, Stef; Itri, Federico; Giordano, Antonio; Pinczés, László Imre; Espigado, Ildefonso; Stojanoski, Zlate; López-García, Alberto; Prezioso, Lucia; Jaksic, Ozren; Vena, Antonio; Fracchiolla, Nicola S.; González-López, Tomás José; Colović, Natasa; Delia, Mario; Weinbergerová, Barbora; Marchetti, Monia; Marques de Almeida, Joyce; Finizio, Olimpia; Besson, Caroline; Biernat, Monika M.; Valković, Toni; Lahmer, Tobias; Cuccaro, Annarosa; Ormazabal-Vélez, Irati; Batinić, Josip; Fernández, Noemí; De Jonge, Nick; Tascini, Carlo; Anastasopoulou, Amalia N.; Duléry, Rémy; Del Principe, Maria Ilaria; Plantefeve, Gaëtan; Papa, Mario Virgilio; Nucci, Marcio; Jiménez, Moraima; Aujayeb, Avinash; Hernández-Rivas, José-Ángel; Merelli, Maria; Cattaneo, Chiara; Blennow, Ola; Nordlander, Anna; Cabirta, Alba; Varricchio, Gina; Sacchi, Maria Vittoria; Cordoba, Raul; Arellano, Elena; Gräfe, Stefanie K.; Wolf, Dominik; Emarah, Ziad; Ammatuna, Emanuele; Hersby, Ditte Stampe; Martín-Pérez, Sonia; Nunes Rodrigues, Raquel; Rahimli, Laman; Pagano, Livio; Cornely, Oliver A. Više autora...

Citirajte ovaj rad

Salmanton García, J., Marchesi, F., Gomes da Silva, M., Farina, F., Dávila Valls, J., Bilgin, Y. M. ... Cornely, O. A. (2023). Nirmatrelvir/ritonavir in COVID-19 patients with haematological malignancies: a report from the EPICOVIDEHA registry. eClinicalMedicine, 58.. doi: 10.1016/j.eclinm.2023.101939

Salmanton García, Jon, et al. "Nirmatrelvir/ritonavir in COVID-19 patients with haematological malignancies: a report from the EPICOVIDEHA registry." eClinicalMedicine, vol. 58, 2023. https://doi.org/10.1016/j.eclinm.2023.101939

Salmanton García, Jon, Francesco Marchesi, Maria Gomes da Silva, Francesca Farina, Julio Dávila Valls, Yavuz M. Bilgin, Andreas Glenthøj, et al. "Nirmatrelvir/ritonavir in COVID-19 patients with haematological malignancies: a report from the EPICOVIDEHA registry." eClinicalMedicine 58 (2023). https://doi.org/10.1016/j.eclinm.2023.101939

Salmanton García, J., et al. (2023) 'Nirmatrelvir/ritonavir in COVID-19 patients with haematological malignancies: a report from the EPICOVIDEHA registry', eClinicalMedicine, 58. doi: 10.1016/j.eclinm.2023.101939

Salmanton García J, Marchesi F, Gomes da Silva M, Farina F, Dávila Valls J, Bilgin YM, i sur.. Nirmatrelvir/ritonavir in COVID-19 patients with haematological malignancies: a report from the EPICOVIDEHA registry. eClinicalMedicine [Internet]. 04.2023. [pristupljeno 23.12.2024.];58. doi: 10.1016/j.eclinm.2023.101939

J. Salmanton García, et al., "Nirmatrelvir/ritonavir in COVID-19 patients with haematological malignancies: a report from the EPICOVIDEHA registry", eClinicalMedicine, vol. 58, Travanj 2023. [Online]. Dostupno na: https://urn.nsk.hr/urn:nbn:hr:105:647221. [Citirano: 23.12.2024.]

Za citiranje koristite ovu mrežnu adresu: https://urn.nsk.hr/urn:nbn:hr:105:647221
Prijavite se u repozitorij kako biste mogli spremiti objekt u svoju listu.
Podaci o radu
Naslov (engleski)Nirmatrelvir/ritonavir in COVID-19 patients with haematological malignancies: a report from the EPICOVIDEHA registry
AutorJon Salmanton-García
AutorFrancesco Marchesi
AutorMaria Gomes da Silva
AutorFrancesca Farina
AutorJulio Dávila-Valls
AutorYavuz M. Bilgin
AutorAndreas Glenthøj
AutorIker Falces-Romero
AutorJaap Van Doesum
AutorJorge Labrador
AutorCaterina Buquicchio
AutorShaimaa El-Ashwah
AutorVerena Petzer
AutorJens Van Praet
AutorMartin Schönlein
AutorMichelina Dargenio
AutorGustavo-Adolfo Méndez
AutorStef Meers
AutorFederico Itri
AutorAntonio Giordano
AutorLászló Imre Pinczés
AutorIldefonso Espigado
AutorZlate Stojanoski
AutorAlberto López-García
AutorLucia Prezioso
AutorOzren Jaksic
AutorAntonio Vena
AutorNicola S. Fracchiolla
AutorTomás José González-López
AutorNatasa Colović
AutorMario Delia
AutorBarbora Weinbergerová
AutorMonia Marchetti
AutorJoyce Marques de Almeida
AutorOlimpia Finizio
AutorCaroline Besson
AutorMonika M. Biernat
AutorToni Valković
AutorTobias Lahmer
AutorAnnarosa Cuccaro
AutorIrati Ormazabal-Vélez
AutorJosip Batinić
AutorNoemí Fernández
AutorNick De Jonge
AutorCarlo Tascini
AutorAmalia N. Anastasopoulou
AutorRémy Duléry
AutorMaria Ilaria Del Principe
AutorGaëtan Plantefeve
AutorMario Virgilio Papa
AutorMarcio Nucci
AutorMoraima Jiménez
AutorAvinash Aujayeb
AutorJosé-Ángel Hernández-Rivas
AutorMaria Merelli
AutorChiara Cattaneo
AutorOla Blennow
AutorAnna Nordlander
AutorAlba Cabirta
AutorGina Varricchio
AutorMaria Vittoria Sacchi
AutorRaul Cordoba
AutorElena Arellano
AutorStefanie K. Gräfe
AutorDominik Wolf
AutorZiad Emarah
AutorEmanuele Ammatuna
AutorDitte Stampe Hersby
AutorSonia Martín-Pérez
AutorRaquel Nunes Rodrigues
AutorLaman Rahimli
AutorLivio Pagano
AutorOliver A. Cornely
KolaboracijaEPICOVIDEHA registry
Autorova ustanovaSveučilište u Zagrebu
Medicinski fakultet
(KATEDRA ZA INTERNU MEDICINU)
Znanstveno / umjetničko
područje, polje i grana		BIOMEDICINA I ZDRAVSTVO
Kliničke medicinske znanosti
Interna medicina
Sažetak (engleski)
Background: Nirmatrelvir/ritonavir treatment decreases the hospitalisation rate in immunocompetent patients with COVID-19, but data on efficacy in patients with haematological malignancy are scarce. Here, we describe the outcome of nirmatrelvir/ritonavir treatment in a large cohort of the latter patients. Methods: This is a retrospective cohort study from the multicentre EPICOVIDEHA registry (NCT04733729) on patients with haematological malignancy, who were diagnosed with COVID-19 between January and September 2022. Patients receiving nirmatrelvir/ritonavir were compared to those who did not. A logistic regression was run to determine factors associated with nirmatrelvir/ritonavir administration in our sample. Mortality between treatment groups was assessed with Kaplan-Meier survival plots after matching all the patients with a propensity score. Additionally, a Cox regression was modelled to detect factors associated with mortality in patients receiving nirmatrelvir/ritonavir. Findings: A total of 1859 patients were analysed, 117 (6%) were treated with nirmatrelvir/ritonavir, 1742 (94%) were treated otherwise. Of 117 patients receiving nirmatrelvir/ritonavir, 80% had received ≥1 anti-SARS-CoV-2 vaccine dose before COVID-19 onset, 13% of which received a 2nd vaccine booster. 5% were admitted to ICU. Nirmatrelvir/ritonavir treatment was associated with the presence of extrapulmonary symptoms at COVID-19 onset, for example anosmia, fever, rhinitis, or sinusitis (aOR 2.509, 95%CI 1.448-4.347) and 2nd vaccine booster (aOR 3.624, 95%CI 1.619-8.109). Chronic pulmonary disease (aOR 0.261, 95%CI 0.093-0.732) and obesity (aOR 0.105, 95%CI 0.014-0.776) were not associated with nirmatrelvir/ritonavir use. After propensity score matching, day-30 mortality rate in patients treated with nirmatrelvir/ritonavir was 2%, significantly lower than in patients with SARS-CoV-2 directed treatment other than nirmatrelvir/ritonavir (11%, p = 0.036). No factor was observed explaining the mortality difference in patients after nirmatrelvir/ritonavir administration. Interpretation: Haematological malignancy patients were more likely to receive nirmatrelvir/ritonavir when reporting extrapulmonary symptoms or 2nd vaccine booster at COVID-19 onset, as opposed to chronic pulmonary disease and obesity. The mortality rate in patients treated with nirmatrelvir/ritonavir was lower than in patients with targeted drugs other than nirmatrelvir/ritonavir.
Ključne riječi (engleski)
Jezikengleski
Vrsta publikacijeZnanstveni rad - Izvorni znanstveni rad
Status objaveObjavljen
Vrsta recenzijeRecenziran
Verzija publikacijeObjavljena verzija rada (izdavačev PDF)
Naslov časopisaeClinicalMedicine
Brojčani podacivol. 58, 101939
p-ISSN2589-5370
DOIhttps://doi.org/10.1016/j.eclinm.2023.101939
URN:NBNurn:nbn:hr:105:647221
Datum objave publikacije2023-04
URL dokumentahttps://linkinghub.elsevier.com/retrieve/pii/S2589537023001165
Vrsta resursaTekst
Prava pristupaOtvoreni pristup
Uvjeti korištenjaIkona licence Imenovanje 4.0 međunarodna (CC BY 4.0)
Datum i vrijeme pohrane2023-12-11 12:39:10